Non-alcoholic fatty liver disease (NAFLD) is a complex spectrum of liver diseases with risk factors almost identical to those of metabolic syndrome, for example; obesity, diabetes, hyperlipidaemia and hypertension. An initial accumulation of lipid in the liver results in simple hepatic steatosis, a relatively benign condition. However, if lipids continue to accumulate and the liver becomes inflamed the disease can progress onto non-alcoholic steatohepatitis (NASH) and fibrosis which can lead to more serious health issues; cirrhosis, hepatocellular carcinoma (HCC) and ultimately end-stage liver disease. Because of the propensity for NASH and fibrosis to progress to end-stage liver disease, with few treatment options available, there is a high level of need to identify and produce drug therapies to correct the underlying metabolic deficits, and to prevent or alleviate hepatic fibrosis and NASH.
RenaSci offer a range of in vivo models of NAFLD, these include dietary-obese rat and mouse models of both simple hepatic steatosis and nutrient-deficient diet (MCD and CD) mouse models of NASH. More novel NASH models utilising a high fat, high fructose, high cholesterol diet in normal (H-FFC) and genetically obese (ob/ob H-FFC) mice and combining the H-FFC diet with the toxin carbon tetrachloride (H-FFC CCl4) are also available. We can also measure liver function and pathology through a range of assays either going hand in hand with an in vivo project or as standalone analysis.
Get in touch to find out more or explore our in vivo models of NASH
For more details or information on how we can support your project please complete the contact form.